Tim protein-bound carrier, methods for obtaining, removing and detecting extracellular membrane vesicles and viruses using said carrier, and kit including said carrier
US-2020393449-A1 · Dec 17, 2020 · US
Angiogenesis agent and method of producing extracellular vesicle having angiogenesis action
US12533381B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12533381-B2 |
| Application number | US-202217864633-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 14, 2022 |
| Priority date | Jan 15, 2020 |
| Publication date | Jan 27, 2026 |
| Grant date | Jan 27, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the angiogenesis agent containing a mesenchymal stem cell-derived extracellular vesicle, as an active ingredient, in which an extracellular vesicle is obtained by a method of using a substance that contains an extracellular vesicle having an affinity for phosphatidylserine, or/and an extracellular vesicle is derived from a mesenchymal stem cell stimulated with a growth factor, and relates to a method of producing an extracellular vesicle as the angiogenesis agent.
First claim
Opening claim text (preview).
What is claimed is: 1 . A method of producing an extracellular vesicle having an angiogenesis action, the method comprising: a step of obtaining an extracellular vesicle from a mesenchymal stem cell-derived extracellular vesicle by a method of using a substance having an affinity for phosphatidylserine. 2 . The method of producing an extracellular vesicle according to claim 1 , wherein the substance having an affinity for phosphatidylserine is a Tim protein. 3 . The method of producing an extracellular vesicle according to claim 2 , wherein the Tim protein is selected from Tim4 protein, Tim3 protein, and Tim1 protein. 4 . The method of producing an extracellular vesicle according to claim 1 , the method further comprising: a step of obtaining a mesenchymal stem cell-derived extracellular vesicle stimulated with a growth factor. 5 . A method of producing an angiogenesis agent, the method comprising a step of obtaining an extracellular vesicle from a mesenchymal stem cell-derived extracellular vesicle by a method of using a substance having an affinity for phosphatidylserine. 6 . The method of producing an angiogenesis agent according to claim 5 , wherein the mesenchymal stem cell is a cell derived from an iPS cell or a cell derived from one or more tissues selected from the group consisting of umbilical cord, umbilical cord blood, bone marrow, adipose, muscle, nerve, skin, amniotic membrane, and placenta. 7 . The method of producing an angiogenesis agent according to claim 5 , the method further comprising: a step of obtaining a mesenchymal stem cell-derived extracellular vesicle stimulated with a growth factor. 8 . The method of producing an angiogenesis agent according to claim 5 , wherein the substance having an affinity for phosphatidylserine is a Tim protein. 9 . The method of producing an angiogenesis agent according to claim 8 , wherein the Tim protein is selected from Tim4 protein, Tim3 protein, and Tim1 protein.
Assignees
Inventors
Classifications
- A61K35/28Primary
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title
Transforming growth factor beta (TGF-β) · CPC title
Basic fibroblast growth factor (bFGF, FGF-2) · CPC title
Vascular endothelial growth factor [VEGF] · CPC title
Mesenchymal stem cells from other natural sources · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12533381B2 cover?
- The present invention relates to the angiogenesis agent containing a mesenchymal stem cell-derived extracellular vesicle, as an active ingredient, in which an extracellular vesicle is obtained by a method of using a substance that contains an extracellular vesicle having an affinity for phosphatidylserine, or/and an extracellular vesicle is derived from a mesenchymal stem cell stimulated with a…
- Who is the assignee on this patent?
- Fujifilm Wako Pure Chemical Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K35/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 27 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).